Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
MWN-AI** Summary
Avacta Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for FAP-Exatecan (AVA6103), marking a significant milestone for the company's pre|CISION® tumor-activated oncology delivery platform. This drug is the second in their pre|CISION® line and is a peptide drug conjugate utilizing the potent topoisomerase I inhibitor, exatecan. With the IND approval, the program transitions from laboratory research to human clinical trials. Avacta plans to initiate a Phase 1 clinical study later in Q1 2026 that will assess the safety and potential efficacy of FAP-Exd in adult patients with four different solid tumors: pancreatic, cervical, gastric, and small cell lung cancer.
The trial's design stems from a strategic collaboration with Tempus AI, utilizing artificial intelligence to identify sensitive markers relating to topoisomerase I inhibitors and fibroblast activation protein (FAP) expressions. Participants will be part of a dose-escalation study testing two administration schedules, with preliminary results expected by late 2026.
CEO Christina Coughlin emphasized the importance of this advancement, noting that the rapid transition from inception to IND clearance in just 24 months reflects the team's dedication and innovation. Chief Medical Officer David Liebowitz highlighted the opportunity this trial presents to deepen the understanding of the pre|CISION® platform's chemistry and validate the potential for various payloads designed to enhance tumor exposure while minimizing systemic toxicity.
Prominent oncologist Dr. Alexander Spira expressed enthusiasm for the project, suggesting that the targeted delivery system might revolutionize cancer treatment by focusing on tumor cells while safeguarding healthy tissues. Avacta remains determined to bring this groundbreaking technology to fruition.
MWN-AI** Analysis
Avacta Therapeutics (AIM: AVCT) has made a significant advancement with the FDA's clearance of its Investigational New Drug (IND) application for FAP-Exatecan (AVA6103), marking a pivotal moment for both the company and its innovative pre|CISION® medicine platform. This clearance allows Avacta to commence the Phase 1 clinical trial anticipated to start in Q1 2026, focusing on various solid tumors, which could potentially position the company at the forefront of oncology therapeutics.
The distinctiveness of AVA6103 lies in its tumor-activated delivery mechanism targeting fibroblast activation protein (FAP), which presents a strategic advantage over traditional therapies by aiming to maximize treatment efficiency while minimizing toxicity. The selection of tumor types—pancreatic, cervical, gastric, and small cell lung cancer—underscores a calculated approach empowered by AI insights, enhancing the trial's potential for success.
Given this context, investors should consider the following: Avacta’s ability to expedite drug development could position it favorably compared to industry standards, suggesting efficiency and a robust pipeline. However, awareness of the biotech sector’s inherent volatility is crucial. Clinical trials are uncertain, and while positive results could significantly enhance investor sentiment and share price, unfavorable outcomes could conversely impact valuation negatively.
Potential stakeholders might find current levels appealing, particularly as the Phase 1 trial results are expected by late 2026, providing a near-term catalyst for price movement. Moreover, with ongoing partnerships (like the collaboration with Tempus AI), Avacta could leverage additional resources and expertise to bolster its clinical endeavors. Therefore, a prudent strategy could involve a balanced approach—investing with consideration of the inherent risks and the potential for substantial returns as milestones are achieved.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026
LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company’s second program FAP-Exd (AVA6103), the first pre|CISION® peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.
The IND approval is an important step in the development of AVA6103 as this is the point where the program moves from the lab into human testing. The Phase 1 clinical trial will evaluate the safety and potential efficacy of FAP-Exd and seek to identify a dose for further clinical development in patients with four solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. The selection of these tumor types was based on an AI approach investigating a sensitivity marker for topoisomerase I inhibitors and FAP expression as part of the strategic collaboration with Tempus AI.
Adult participants will be enrolled in the dose-escalation part of the trial with two parallel arms investigating two schedules of administration (every two weeks, Q2W and every three weeks, Q3W) with preliminary data from this trial anticipated in the second half of 2026.
Christina Coughlin, MD, PhD, Chief Executive Officer at Avacta Therapeutics commented,
“Taking FAP-Exd into the clinic is a critical milestone for the pre|CISION® platform and for the Company. In moving the FAP-Exd program forward from inception to a cleared IND in just 24 months, our team has exceeded industry standard timelines. The sustained release mechanism of FAP-Exd, invented by Avacta, is expected to enable greater efficacy in the clinic while limiting the toxicities that were observed with exatecan in its original clinical development. We are very excited to move this program forward for patients and shareholders alike.”
David Liebowitz, MD, PhD, Chief Medical Officer at Avacta Therapeutics added,
“Our FAP-Exd program in the clinic will very soon provide a greater understanding of the new chemistry of the pre|CISION® platform and also validate the potential to move forward with varied payloads based on our novel capping group and linker technologies. This new program will support a greater understanding of our technology’s broad applicability and validate our ability to design molecules that maximize the exposure of our payloads in the tumor in patients.”
Alexander Spira MD, PhD, FACP, FASCO, Co-Director, Virginia Cancer Specialists (VCS) Research Institute; Director, VCS Thoracic and Phase 1 Program; Chief Scientific Officer, NEXT Oncology; and Clinical Assistant Professor, Johns Hopkins also commented:
“I am thrilled to work with Avacta on this exciting new drug. The ability to concentrate a potent topoisomerase I inhibitor directly in the tumor while protecting normal tissues from harmful effects is the next stage of how we should be treating cancer. We are looking forward to participating in this second pre|CISION® Phase 1 trial and helping the Company to drive this pioneering technology forward.”
For further information from Avacta, please contact:
| Avacta Group plc Christina Coughlin, Chief Executive Officer | https://avacta.com/ via ICR Healthcare |
| Strand Hanson Limited (Nominated Adviser) James Harris / Chris Raggett / James Dance | www.strandhanson.co.uk |
| Zeus (Broker) James Hornigold / George Duxberry / Dominic King | www.zeuscapital.co.uk |
| ICR Healthcare Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert | avacta@icrhealthcare.com |
| Investor Contact Renee Leck THRUST Strategic Communications | renee@thrustsc.com |
| Media Contact Carly Scaduto | Carly@thrustsc.com |
About Avacta - https://avacta.com/
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues.
Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.
The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.
FAQ**
What key milestones does Avacta Group Plc AVCTF anticipate achieving during the Phase 1 clinical study of FAP-Exd (AVA6103) that may influence future funding and investor confidence?
How might the outcomes of the Phase 1 trial impact Avacta Group Plc AVCTF's strategic decisions regarding the potential expansion of the pre|CISION® platform beyond the initial tumor types being studied?
In what ways does the feedback from clinical experts, such as Alexander Spira MD, contribute to shaping the future direction of Avacta Group Plc AVCTF's research and development efforts surrounding FAP-Exd (AVA6103)?
Given the anticipated preliminary data release in the second half of 2026, what are the potential implications for Avacta Group Plc AVCTF’s stock performance if the results meet or exceed market expectations?
**MWN-AI FAQ is based on asking OpenAI questions about Avacta Group Plc (OTC: AVCTF).
NASDAQ: AVCTF
AVCTF Trading
0.0% G/L:
$0.9794 Last:
100 Volume:
$0.9794 Open:
